drugset / Trial / NCT01411735

Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure

NCT01411735

Phase 3 Completed 71 enrolled Wake Forest University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

BACKGROUND: Exercise intolerance is the primary symptom in older patients with heart failure and preserved ejection fraction (HFPEF), however little is known regarding its mechanisms and therapy. METHODS: 71 elderly stable, compensated HFPEF patients (age 70+1 years; 80% women) with controlled blood pressure were randomized into a 12 month follow-up (FU) double-blind trial of enalapril 20 mg per day (E) vs. placebo (P). Assessments included: peak exercise oxygen consumption (VO2); six-minute walk test; Minnesota Living with HF Questionnaire (MLHF); MRI; Doppler-echocardiography; and vascular ultrasound.

Timeline

Start
2003-07
Primary completion
2004-06
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enalapril Other / unclassified 10 mg